Details for Patent: 8,895,064
✉ Email this page to a colleague
Which drugs does patent 8,895,064 protect, and when does it expire?
Patent 8,895,064 protects UCERIS and is included in one NDA.
This patent has twenty-six patent family members in seventeen countries.
Summary for Patent: 8,895,064
| Title: | Controlled release and taste masking oral pharmaceutical composition |
| Abstract: | Controlled release and taste masking compositions containing one or more active principles inglobated in a three-component matrix structure, i.e. a structure formed by successive amphiphilic, lipophilic or inert matrices and finally inglobated or dispersed in hydrophilic matrices. The use of a plurality of systems for the control of the dissolution of the active ingredient modulates the dissolution rate of the active ingredient in aqueous and/or biological fluids, thereby controlling the release kinetics in the gastrointestinal tract. |
| Inventor(s): | Villa; Roberto (Lecco, IT), Pedrani; Massimo (Gignese, IT), Ajani; Mauro (Milan, IT), Fossati; Lorenzo (Milan, IT) |
| Assignee: | Cosmo Technologies Limited (Dublin, IE) |
| Application Number: | 13/226,758 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 8,895,064 |
|
Patent Claim Types: see list of patent claims | Composition; Dosage form; |
Drugs Protected by US Patent 8,895,064
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Salix | UCERIS | budesonide | TABLET, EXTENDED RELEASE;ORAL | 203634-001 | Jan 14, 2013 | AB | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
